← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Avidbiotics Corporation
South San Francisco, CA
$5,881,354
Total funding
10
Grants
Funding over time
peak $1.6M · FY2006–18$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,881,354 · 10
By mechanism
R43$3,466,832 · 6
R44$1,073,420 · 1
R21$816,847 · 2
R33$524,255 · 1
Investigators at Avidbiotics Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Non-clinical Development of Bactericidal Proteins Targeting Plague$602,645
R44 · FY2009 · AI
Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs$524,255
R33 · FY2018 · AI
HOST RANGE DIVERSITY OF BACTERIOPHAGE FOR Y. PESTIS$494,982
R43 · FY2006 · AI
Non-clinical Development of Bactericidal Proteins Targeting Plague$470,775
R44 · FY2010 · AI
Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs$324,080
R21 · FY2016 · AI
Engineered R-type pyocins as bactericidal agents against E.coli O157:H7$317,576
R43 · FY2010 · AI
Engineered R-type pyocins as bactericidal agents against E.coli O157:H7$317,576
R43 · FY2009 · AI
DIVERSIFYING MICA TO CREATE TARGETED ADAPTERS TO RECRUIT AND ACTIVATE NK CELLS TO$316,078
R43 · FY2013 · TR
Engineered R-type pyocins as bactericidal agents against E.coli O157:H7$308,517
R43 · FY2011 · AI
Targeted soluble MICA molecules to recruit innate immunity cells to kill specific$300,000
R43 · FY2011 · AI
TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE$300,000
R43 · FY2012 · AI
TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE$300,000
R43 · FY2013 · AI
Targeted soluble MICA molecules to recruit innate immunity cells to kill specific$300,000
R43 · FY2010 · AI
Create, evaluate and develop pre-clinically an engineered R-type pyocin to specif$284,032
R43 · FY2010 · AI
Create, evaluate and develop pre-clinically an engineered R-type pyocin to specif$228,071
R43 · FY2011 · AI
Generating a library of antimicrobial R-type pyocins against enteric bacteria$200,000
R21 · FY2010 · AI
Generating a library of antimicrobial R-type pyocins against enteric bacteria$173,250
R21 · FY2011 · AI
Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs$119,517
R21 · FY2017 · AI